Skip to content

Abstract B025: Multiple domains contribute to nucleosome invasion by EWSR1::FLI1

Sep 2026 · Cancer Research · 0 citations

TL;DR

New insights are revealed into how EWSR1::FLI1 binds to DNA motifs in chromatin and it is suggested that the EWSR1 LCD may contribute to both altered sequence-specific DNA binding and nucleosome engagement.

Abstract

Ewing sarcoma is a rare and aggressive pediatric cancer caused by a translocation-derived fusion oncoprotein that fuses the N-terminal low complexity domain (LCD) of a FET protein (FUS, EWSR1, or TAF15) with the C-terminal portion of an ETS transcription factor from the ERG or PEA3 subfamilies. These fusion oncoproteins retain the conserved ETS winged helix-loop-helix (wHLH) DNA binding domain and function as aberrant transcription factors to alter gene regulation and promote oncogenesis. The most common fusion in this disease is EWSR1::FLI1. Because EWSR1::FLI1 functions as a master regulator of cell fate, it is proposed to be a pioneer transcription factor (PF). PFs recognize and bind their motifs in closed chromatin, facilitate chromatin opening, and recruit ATP-dependent chromatin remodelers to establish lineage-specific gene expression programs. EWSR1::FLI1 has been shown to bind at both the FLI1 high affinity (HA) motif (5’-ACCGGAAGTG-3’) and repetitive GGAA microsatellites. Genomic profiling shows that EWSR1::FLI1-bound regions become more accessible with GGAA microsatellite binding frequently resulting in de novo enhancer formation. However, other studies have shown context-specific binding of EWSR1::FLI1 to GGAA repeats in closed chromatin and the importance of binding at HA ETS sites for tumor initiation. The ability of EWSR1::FLI1 to recognize and bind nucleosomal motifs and the molecular mechanisms by which it may do so remain poorly understood. Here we use purified recombinant truncated FLI1 wHLH and full-length EWSR1::FLI1 constructs in in vitro biochemical and fluorescence experiments to better understand how the DBD of EWSR1::FLI1 interacts with DNA and nucleosomes. While both the FLI1 wHLH and full-length EWSR1::FLI1 display efficient nucleosome invasion, we identify significant differences in sequence-specific binding to both DNA and nucleosomes between the full-length protein and truncated constructs, suggesting the EWSR1 LCD modulates both DNA sequence recognition and nucleosome engagement. Our findings reveal new insights into how EWSR1::FLI1 binds to DNA motifs in chromatin and suggest that the EWSR1 LCD may contribute to both altered sequence-specific DNA binding and nucleosome engagement. These studies establish an experimental framework for future investigations of the different factors that influence nucleosome engagement by EWSR1::FLI1 to cause Ewing sarcoma in cells. Ruo-Wen Chen, Runwei Zhou, E John. Tokarsky, Megann A. Boone, Andrea Byrum, Michael G. Poirier, Emily R. Theisen. Multiple domains contribute to nucleosome invasion by EWSR1::FLI1 [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Bridging Discovery and Clinical Impact in Pediatric Cancer; 2026 Sep 22-25; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_1):Abstract nr B025.

View source

Similar papers

Open access Sep 2026

Fusion Oncoprotein EWSR1::FLI1 Invades Nucleosomes at Consensus ETS Motifs and GGAA Microsatellites

It is revealed that EWSR1::FLI1 possesses a key pioneer factor property, efficiently targeting its binding site within nucleosomes, and that full-length EWSR1::FLI1 binding shifts to preferentially target GGAA repeats, even on motifs that bind a single EWSR1::FLI1 protein.

Ruo-Wen Chen, R. Zhou, E. J. Tokarsky et al. · 0 citations
Open access Aug 2026

RERE and the Mediator complex cooperate with EWSR1::FLI1 in the reprogramming of Translation and Alternative Splicing, the latter being a therapeutically targetable vulnerability in Ewing sarcoma

The identification of the splicing factor RBM39 as a vulnerability in ES is supported by the extraordinary sensitivity of these tumors to monotherapy with RBM39 degrader indisulam, highlighting the potential of this approach as a novel and promising therapeutic strategy for Ewing sarcoma.

Irene Cuervas, Sophie Bonnal, Evelyn Andrades et al. · 0 citations
Sep 2026

Abstract IA05: Biology and therapeutic targeting of NUP98 fusion oncoprotein condensates

It is shown that genetic knockout of Brpf1 as well as Kat6a, Kat7, and a subset of other HAT complex members led to decreased cell fitness, and pharmacologic inhibition of KAT6A/7 using small molecule inhibitor PF9363 was effective in multiple preclinical models of NUP98-rearranged leukemia.

N. Michmerhuizen, Ella Monfort, Z. G. Soares et al. · 0 citations
Open access Sep 2026

The Drosophila FET ortholog Cabeza is an essential cofactor for ETV4-mediated activation of GGAA microsatellite neoenhancers.

In vivo evidence that non-fused ETS factors cooperate with endogenous FET proteins to drive transcription from silent GGAA repeats is provided, mechanistically validating this regulatory transformation known to operate as an oncogenic mechanism beyond Ewing sarcoma.

Cristina Molnar, Jose Reina, J. Mora et al. · 0 citations
Sep 2026

Abstract B005: Synergistic targeting of EP300/CBP and EYA co-activators collapses the rhabdomyosarcoma core regulatory circuit

Rhabdomyosarcoma (RMS) is a high-risk pediatric sarcoma that resembles developing skeletal muscle. Transcriptional dysregulation drives RMS pathogenesis in tumors carrying chimeric transcription factors (“fusion-positive (FP)”), and those without (“fusion-negative” (FN)). Here, we develop a novel approach against RMS...

Brian J. Abraham, Annika L. Gustafson, S. Nance et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.